Aequitas Announces Reimbursement Roadmap Seminar; Research and Analysis Firm Teams with BIO to Present Reimbursement Information to Biotechnology and Investor Communities.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Aequitas, a highly regarded strategic healthcare advisory firm, in conjunction with the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. from 2:30 p.m.- 5:30 p.m. Persons who are interested in attending may register at www.reimbursementroadmap.com or contact Heide Bajnrauh at 858-847-9126. Investment in healthcare companies requires a sophisticated understanding of third-party reimbursement associated with their products and services. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval does not guarantee sales or market share. Payers, including insurance companies and health plans, continue to scrutinize scru·ti·nize tr.v. scru·ti·nized, scru·ti·niz·ing, scru·ti·niz·es To examine or observe with great care; inspect critically. scru adoption and payment for new technology. The Reimbursement Roadmap(TM) series explores the perspectives used by payers for their evaluation of new healthcare technology, and explains how such efforts impact product and company valuation. Attendees will have the opportunity to learn more regarding: --CMS and changes to the reimbursement system due to the passage of the Medicare Modernization Act; --Private Commercial Payers and how to obtain coverage, which leads to reimbursement; and --Developing a Reimbursement Strategy. "With companies under relentless pressure to commercialize successful products, meet investor expectations, and grow earnings, it is no surprise that no opportunity for enhancing performance is overlooked. Yet establishing third-party reimbursement remains a poorly understood and often-missed occasion for assuring appropriate product valuation and pricing," stated Frank J. Papatheofanis, MD, MPH, PhD, president and chief executive officer of Aequitas. "Companies that integrate R&D, marketing, and reimbursement strategies are in a better position to understand the likelihood of commercial success and the factors that will drive it." Speakers include Frank Papatheofanis, MD, MPH, PhD, president and CEO of Aequitas; Cynthia Davis, director of equity and investment research for Aequitas; and Jayson Slotnik, director of Medicare reimbursement and economic policy, Biotechnology Industry Organization. About Aequitas Aequitas is a leading independent research and analysis firm that specializes in the development of evidence-based product valuation and provides solutions to support the development, management, and marketing of new and existing technologies throughout the healthcare industry. About BIO BIO represents more than 1,000 biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. , academic institutions, state biotechnology centers, and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology Environmental biotechnology is when biotechnology is applied to and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. products. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion